1. Home
  2. IMMX

as 06-18-2024 9:30am EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Medicinal Chemicals and Botanical Products

Nasdaq

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Founded: 2014 Country:
United States
United States
Employees: N/A City: LOS ANGELES
Market Cap: 65.2M IPO Year: 2021
Target Price: $14.00 AVG Volume (30 days): 128.5K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.93 EPS Growth: N/A
52 Week Low/High: $1.55 - $7.75 Next Earning Date: 08-09-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

IMMX Daily Stock ML Predictions

Stock Insider Trading Activity of Immix Biopharma Inc. (IMMX)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Morris Gabriel S IMMX CFO Jun 7 '24 Buy $2.12 2,500 $5,298.00 285,834 SEC Form 4
Rachman Ilya M IMMX CEO and Chairman Jun 7 '24 Buy $2.13 2,600 $5,538.00 1,136,259 SEC Form 4
Morris Gabriel S IMMX CFO Jun 4 '24 Buy $1.81 3,300 $5,972.67 283,334 SEC Form 4
Morris Gabriel S IMMX CFO May 14 '24 Buy $2.23 4,500 $10,041.75 85,816 SEC Form 4
Rachman Ilya M IMMX CEO and Chairman May 14 '24 Buy $2.25 4,300 $9,659.95 912,000 SEC Form 4
Hsu Jason IMMX Director Dec 8 '23 Buy $4.88 25,000 $122,025.00 782,000 SEC Form 4
Hsu Jason IMMX Director Dec 8 '23 Buy $4.67 31,000 $144,894.00 813,000 SEC Form 4

Share on Social Networks: